Future studies should investigate whether PAC1 activation can enhance remyelination or neuroprotection in demyelinating disease models, potentially advancing its relevance as a therapeutic target in MS and/or other demyelinating disorders. Here, ADCYAP1R1 is linked to myeloid sarcoma.